Safety Evaluation of LSCD101 Transplantation for Limbal Stem Cell Deficiency

Summary

Clinical Study Objective: To evaluate the tolerability and safety after transplantation of LSCD101 in patients with intractable limbal stem cell deficiency Study Method: Subjects who finally meet the inclusion/exclusion criteria results of the subject eligibility evaluation will receive transplantation of the investigational product. Adverse drug reaction will be confirmed during 24 weeks after transplantation.

Timeline

Start

2020-01-31

Primary completion

2021-01-14

Completion

2021-01-14

Drugs

Indications